Clinical experience with cyclooxygenase-2 inhibitors

Inflammation Research

Volumn 48, Issue 5, 1999, Pages 247-254

  Van Ryn, J ^a   Pairet, M ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

COX 1; COX 2; Cyclooxygenase; Non steroidal anti inflammatory drugs (NSAIDs)

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; MELOXICAM; NIMESULIDE; ROFECOXIB;

INFLAMMATION; REVIEW;

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SUBSTRATE SPECIFICITY;

EID: 0033057783     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050455     Document Type: Review

References (97)

1. [1] Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature (New Biol) 1971; 231: 232-5.
2. [2] Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-40.
3. [3] Fletcher BS, Kujubu DA, Perrin DM, Herschmann HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992; 267: 4338-44.
4. [4] Vane JR. Towards a better aspirin. Nature 1994; 367: 215-6.
5. [5] Akarasereenont P, Mitchell JA, Appleton I, Thiemermann C, Vane JR. Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol 1994;113:1522-8.
6. [6] Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun 1995; 208: 582-9.
7. [7] Swierskosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 1995; 114: 1335-42.
8. [8] Barrios-Rodiles M, Keller K, Belley A, Chadee K. Nonsteroidal antiinflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages. Biochem Biophys Res Commun 1996; 225: 896-900.
9. [19] Misko TP, Trotter JL, Cross AH. Mediation of inflammation by encephalogenic cells: Interferon induction of nitric oxide synthase and cyclooxygenase 2. J Neuroimmunol 1995; 61: 195-204.
10. [10] Quinn MR, Park E, Schuller-Levis G. Taurine chloramine inhibits prostaglandin E2 production in activated raw 264.7 cells by posttranscriptional effects on inducible cyclooxygenase expression. Immunol Lett 1996; 50: 185-8.
11. [11] Thivierge M, Rola-Pleszczynski M. Up-regulation of inducible cyclooxygenase gene expression by platelet-activating factor in activated rat alveolar macrophages. J Immunol 1995; 154: 6593-9.
12. [12] Tordjman C, Coge F, Andre N, Rique H, Spedding M, Bonnet J. Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro; interactions of non steroidal anti-inflammatory drugs with COX2. Biochim Biophys Acta 1995; 1256: 249-56.
13. 2 stimulation. Exp Cell Res 1996; 222: 379-84.
14. [14] de Brum-Fernandes AJ, Laporte S, Heroux M, Lora M, Patry C, Ménard HA, et al. Expression of prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide syntnase-2 in human osteoblasts. Biochem Biophys Res Commun 1994; 198: 955-60.
15. [15] Szczepanski A, Moatter T, Carley WW, Gerritsen ME. Induction of cyclooxygenasc II in human synovial microvessel endothelial cells by interleukin-1. Arthritis Rheum 1994; 37: 495-503.
16. [16] Nüsing R, Ullrich V. Regulation of cyclooxygenase and thromboxane synthase in human monocytes. Eur J Biochem 1992; 206: 131-6.
17. 2-isoprostane formation. Br J Pharmacol 1996; 118: 1285-93.
18. [18] Lee SH, Soyoola E, Chanmungam P, Hart S, Sun W, Zhong H, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267: 25934-8.
19. [19] Niro H, Otsuka T, Tanabe T, Hara S, Kuga S, Nemoto Y, et al. Inhibition by interleukin-10 of inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: its underlying mechanism in comparison with interleukin-4, Blood 1995; 85: 3736-45.
20. [20] Endo T, Ogushi F, Sone S. LPS-dependent cyclooxygenase-2 induction in human monocytes is down-regulated by IL-13, but not IFN-γ. J Immunol 1996; 156: 2240-6.
21. [21] Mertz PM, DeWitt DL, Stetler-Stevenson WG, Wahl LM. Interleukin 10 suppression of monocyte prostaglandin H synthase-2. J Biol Chem 1994; 269: 21322-9.
22. [22] Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-7.
23. [23] Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91; 3228-32.
24. [24] Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part 2. In vivo findings Biochem Pharmacol 1996; 51: 29-38.
25. [25] Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Naciag T, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992; 89:97-108.
26. [26] Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672-9.
27. [27] Engelhardt G, Homma D, Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the lewis rat. Inflamm Res 1995; 44: 548-55.
28. [27] Tomlinson A, Appleton I, Moore AR, Gilroy DW, Willis D, Mitchell JA, et al. Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin induced pleurisy. Br J Pharmacol 1994; 113: 693-8.
29. [29] Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fund Clin Pharmacol 1996; 10: 1-15.
30. [30] Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046-50.
31. [31 ] Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1 β, phorbol ester and corticostcroids. J Clin Invest 1994; 93: 1095-101.
32. [32] Crofford LJ. Expression and regulation of cyclooxygenase-2 in synovial tissues of arthritic patients. In: Bazan N, Botting J, Vane J, editors. New targets in inflammation: inhibitors of COX-2 or adhesion molecules. Dordrecht: Kluwer Academic Publishers, 1996: 83-91.
33. [33] Carreira PE, Iniquez MA, Pablos JL, Cabré F, Gomez-Reino JJ. Detection of COX-1 and COX-2 isoforms in synovial fluid from patients with inflammatory joint diseases. Arthritis Rheum 1996; 39 (Suppl 9): Abstract 327.
34. [34] Franz JK, Hummel KM, Aicher WK, Petrow PK, Gay RE, Gay S. In-situ detection of cyclooxygenase (COX) 1 and 2 mRNA in rheumatoid arthritis (RA) and osteoarthritis (OA) synovium. Arthritis Rheum 1996; 39 (Suppl 9): Abstract 1021.
35. [35] van Ryn J, Pairet M. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Exp Opin Invest Drugs 1997; 6: 609-14.
36. [36] Pairet M, van Ryn J, Mauz A, Schierok H, Diederen W, Türck D, et al. Differential inhibition of COX-1 and COX-2 by NSAIDs: A summary of results obtained using various test systems. In: Vane J, Botting J, editors. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Dordrecht: Kluwer Academic Publishers, 1998: 27-46.
37. [37] Swingle KF, Moore GGI. Preclinical pharmacological studies with nimesulide. Drugs Exp Clin Res 1984; 10: 587-97.
38. [38] Martel RR, Klicius J. Comparison in rats of the anti-inflammatory and gastric irritant effects of etodolac with several clinically effective anti-inflammatory drugs. Agents Actions 1982; 12: 295-7.
39. [39] Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997; 121: 105-17.
40. [40] Penning TD, Talley JJ, Berteshaw SR, Carter JS, Collins PW, Docter SD, et al. Synthesis and biological evaluation of the 1,5 diarylpyrazol class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58735, celecoxib). J Med Chem 1997; 40: 1347-65.
41. [41] Pairet M, Churchill L, Engelhardt G. Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs. In: Bazan N, Botting J, Vane J, editors. New targets in inflammation: inhibitors of COX-2 and adhesion molecules. Dordrecht: Kluwer Academic Publishers, 1996: 23-38.
42. [42] Klein T, Nüsing R, Pfeilschifter J, Ulrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994; 48: 1605-10.
43. [43] Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996; 45: 68-74.
44. [44] Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible form of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994; 91: 11202-6.
45. [45] Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem Pharmacol 1996; 51: 21-8.
46. [46] Mitchell JA, Belvisi MG, Akarasereenont P, Robbins RA, Kwon OJ, Croxtall J, et al. Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 1994; 113: 1008-14.
47. [47] Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994; 1209: 130-9.
48. [48] Wong E, DeLuca C, Boily C, Charleson S, Cromlish W, Denis D, et al. Characterization of autocrine inducible prostaglandin H synthase 1 (PGHS-2) in human osteosarcoma cells. Inflamm Res 1997; 46: 51-9.
49. [49] Prasit P, Black WC, Chan CC, Ford-Hutchinson AW, Gauthier JY, Gordon R, et al. L-745,447: a selective cyclooxygenase-2 inhibitor. Med Chem Res 1995; 5: 364-74.
50. [50] Lazer ES, Miao CK, Cywin CL, Soreek R, Wong H-C, Meng Z, et al. Effect of structural modification of enol caboxamide type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J Med Chem 1997; 40: 980-9.
51. [51] Churchill L, Graham A, Shih CK, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 1996; 4: 125-35.
52. [52] Patrignani P, Panara MR, Santini G, Sciulli MG, Padovano R, Cipollone F, et al. Differential inhibition of cyclooxygenase activity and prostaglandin endoperoxide synthase isozymes in vitro and ex vivo in man. Prostagland Leukotr Essen Fatty Acids 1996; 55 (Suppl 1): Abstract P115.
53. 2 production. Inflamm Res 1996; 45; 246-53.
54. [54] Cromlish L, Kennedy BP. Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays Biochem Pharmacol 1996; 52; 1777-85.
55. [55] Stichtenoth DO, Wagner B, Frölich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers, J Invest Med 1997; 45: 44-9.
56. [56] Cullen L, Kelly L, Coyle D, Forde R, Fitzgerald D. Selective suppression of COX-2 during chronic administration of nimesulide in man. William Harvey Research Conference: Selective COX-2 Inhibitors; pharmacology, clinical effects and therapeutic potential, Cannes, 20-21 March 1996, Abstract P3.
57. [57] Steinhäuslin F, Munajo A, Buclin T, Macciochi A, Biollaz J. Renal effects of nimesulide in furosemide-treated subjects. Drugs 1993; 46 (Suppl 1): 257-62.
58. [58] Taha AS, McLaughlin S, Holland PJ, Kelly RW, Sturrock RD, Russell RI. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of naproxen and etodolac in rheumatoid arthritis. Ann Rheum Dis 1990; 49: 354-8.
59. [59] Russell RI. Endoscopic evaluation of etodolac and naproxen and their relative effects on gastric and duodenal prostaglandins. Rheumatol Int 1990; 10: 17-21.
60. [60] Schwartz B, Hurley SM, Hubbard RC, Yu SS, Talwalker S, Isakson P, et al. A pilot study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor. ILAR Congress of Rheumatology, Singapore, 8-13 June 1997, Abstract Book, p. 159.
61. [61] Ehrich E, Dallob A, Van Hacken A, Depré M, DeLepeleire I, DeSchepper C, et al. Demonstration of selective COX-2 inhibition by MK-966 in humans. Arthritis and Rheumatism 1996; 39 (Suppl 9): Abstract 328.
62. [62] Patoia E, Santucci L, Furno M, Dionisi MS. Dell'Orso M, Romagnoli M, et al. A 4-week double-blind parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996; 35 (Suppl 1): 61-7.
63. [63] Cipollini F, Mecozzi V, Atilia F. Endoscopic assessment of the effects of nimesulide on the gastric mucosa: comparison with indomethacin. Curr Ther Res 1989; 45: 1042-7.
64. [64] Marini U, Spotti D, Magni E, Monti T. Double-blind endoscopic study comparing the effect of nimesulide and placebo on gastric mucosa of dyspeptic subjects. Drug Invest 1990; 2: 162-6.
65. [65] Lanza F, Rack NW, Lynn M, Wolf J, Sanda M. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 1987; 14: 338-41.
66. [66] Lanza F, Panagides J, Salom IL. Etodolac compared with aspirin: an endoscopic study of gastrointestinal tracts of normal volunteers. J Rheumatol 1986; 13; 299-303.
67. [67] Van Eeden A, Schotborgh RH, Tygat GNJ. An endoscopic evaluation of the effects of etodolac and diclofenac on the gastric and duodenal mucosa. Clin Ther 1990; 12; 496-502.
68. [68] Lanza FL, Rack MF, Callison DA, Hubbard RC. A pilot endoscopic study of the gastroduodenal effects of SC-58635. Gasteroenterology 1997; 112 A194.
69. [69] Lanza FL, Simon T, Quan H, Bolognese J, Rack MF, Hoover M, et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg q.d.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg q.i.d. or ibuprofen (IBU) 800 mg t.i.d. Gasteroenterology 1997; 112: A194.
70. [70] Lund B, Distel M, Bluhmki E. A double-blind placebo controlled study of three different doses of meloxicam in patients with osteoarthritis of the knee. Scand J Rheumatol 1994; Suppl 98: Abstract 117.
71. [71] Goei The H, Lund B, Distel M, Bluhmki E. A double-blind randomised trial comparing meloxicam with diclofenac in osteoarthritis. Rheumatology in Europe 1995; 24 (Suppl 3): 325, Abstract E51.
72. [72] Hosie J, Distel M, Bluhmki E. A six month, double-blind study comparing meloxicam 15 mg with piroxicam 20 mg in osteoarthritis. Rheumatol Europe 1995; 24 (Suppl 3): 325, Abstract E50.
73. [73] Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a six-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996; 35 (Suppl 1); 39-43.
74. [74] Lindén B, Distel M, Bluhmki F. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35 (Suppl 1): 35-8.
75. [75] Lemmel EM, Bolten W, Burgos-Vargas R, Platt P, Nissilä M, Sahlberg D, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997; 24: 282-90.
76. [76] Bolten W. Clinical experience with meloxicam, a selective COX-2 inhibitor. In: Bazan N, Botting J, Vane J, editors. New targets in inflammation: inhibitors of COX-2 and adhesion molecules. Dordrecht: Kluwer Academic Publishers, 1996: 105-16.
77. [77] Distel M, Mueller C, Bluhmki E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology 1996; 4: 71-81.
78. [78] Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431-54.
79. [79] Bourgeois P, Dreiser RL, Lequesne MG, Macciocchi A, Monti T. Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur J Rheumatol Inflamm 1994; 14: 39-50.
80. [80] Lücker PW, Pawlowski C, Friedrich I, Faiella F, Magni E. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodolac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm 1994; 14: 29-38.
81. [81] Quattrini M, Paladin S. A double-blind study comparing nimesulide with naproxen in the treatment of osteoarthrosis of the hip. Clin Drug Invest 1995, 10: 139-46.
82. [82] Balfour JA, Buckley MMT. Etodolac: A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs 1991; 42: 274-99.
83. [83] Bacon PA. An overview of the efficacy of etodolac in arthritic disorders. Eur J Rheumatol Inflamm 1990; 10: 22-34.
84. [84] Paulsen GA, Baigun S, de Figueiredo JG, de Freitas GG. Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee. Curr Med Res Opin 1991; 12: 40-1.
85. [85] Schnitzer TJ, Constantine G. Etodolac in the treatment of osteoarthritis, recent studies. J Rheumatol 1994; 24 (Suppl 47): 23-31.
86. [86] Spencer-Green G. Low dose etodolac in rheumatoid arthritis: a review of early studies. J Rheumatol 1997; 24 (Suppl 47): 3-9.
87. [87] Lightfoot R. Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. J Rheumatol 1997; 24 (Suppl 47): 10-6.
88. [88] Neustadt DH, Double-blind evaluation of the longterm effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol 1997; 24 (Suppl 47): 17-22.
89. [89] Hubbard RC, Koepp R, Yu SS, Talwalker S, Geis GS, Weisenhutter CW, et al. A pilot study of the efficacy of SC-58635, a novel COX-2 selective inhibitor, in treating osteoarthritis. ILAR Congress of Rheumatology, Singapore, 8-13 June 1997: 46.
90. [90] Lipsky PE. COX-2 inhibition in patients with arthritis: Theory and practice. APLAR J Rheumatol 1997; 1: 69-72.
91. [91] Isakson P, Zweifel B, Masferrer J, Kobolt C, Seibert K, Hubhard R, et al. Specific COX-2 inhibitors: from bench to bedside. In: Vane J, Botting J, editors. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Dordrecht: Kluwer Academic Publishers, 1998: 127-33.
92. [92] Ehrich E, Schnitzer T, Mcilwain H, Levy R, Wolfe F, Weisman W, et al. MK-966, a highly selective COX-2 inhibitor, is effective in the treatment of osteoarthritis in a 6-week pilot study. ILAR Congress of Rheumatology, Singapore, 8-13 June 1997: 47.
93. [93] Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Bégaud B, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937-45.
94. [94] Dequcker J, Hawkey C, Kahan A, Steinbrück K, Alegre C. Baumelou E, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase COX-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large Scale Evaluation of COX inhibition Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-51.
95. [95] Zeidler H, Degner F, Hettich M. Comparative pharmacoepidemiologic analysis of gastrointestinal safety of selective COX-2 inhibition by meloxicam compared to other marketed NSAIDs. Eur J Clin Pharmacol 1997; 52 (Suppl): Abstract 327.
96. [96] Singh G, Terry R, Ramey D, Halpern J, Brown WB. Comparative GI toxicity of NSAIDs. ILAR Congress of Rheumatology, Singapore, 8-13 June 1997: 159.
97. [97] Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158: 33-9.